| Purpose:investigate the effectiveness of simvastatin for the treatment of chronic heart failure patients and clinical observation on interleukin (IL-1), brain natriuretic peptide (BNP), adiponectin Su (APN) levels.Method:selected patients with heart failure were randomly divided into two groups and the control group 40 patients, two groups were given conventional therapy, observed in the conventional treatment group given simvastatin 10mg,1 per night, with a course 1 year.1 day before treatment and 3 months after treatment,12 months, a heart ultrasound test cardiac function:left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVDD), interventricular septum thickness and left ventricular end-diastolic wall thickness and detection of 6min walk test, Minnesota quality of life score, serum IL-1, BNP, APN; record readmission rates and adverse events within the study period.Results:in the initial study period the experimental group and control group showed no significant difference observed; efficiency and the observation group were significantly higher than the total effective rate; observation group in the study period the first 3 months, 12 months 6min walk distance is greater than the control group (P<0.05); observation group in the study period the first 3 months,12 months, the Minnesota quality score, plasma NT-proBNP, APN lower than the control group (P<0.05); in the study cycle, the first 3 months and 12 months of observation group left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVDD), were significantly improved after treatment group, IL-1, BNP, APN levels than significantly lower before treatment, and reduce the level of the observation group than the control group (P<0.05).Conclusion:chronic non-ischemic heart failure patients in the conventional treatment based on the use of simvastatin 10m/day treatment for 3 months and 12 months of treatment could significantly improve left ventricular function and endothelial function, reduce blood IL-1, BNP, APN levels, improve the quality of life of patients and reduce readmission rates and mortality. No serious adverse reactions. Simvastatin in chronic non-ischemic cardiac function in heart failure patients may be inhibited by anti-inflammatory effects and the development of myocardial remodeling and heart failure delayed implementation, independent of the lipid-lowering outside. APN and NT-proBNP levels in the observation process are similar trends, indicating a high degree of correlation between the two. |
PDF Full Text Request